Bruce G. Allen Investments LLC Sells 364 Shares of GSK plc (NYSE:GSK)

Bruce G. Allen Investments LLC decreased its stake in shares of GSK plc (NYSE:GSK) by 6.0% in the first quarter, Holdings Channel.com reports. The fund owned 5,749 shares of the pharmaceutical company’s stock after selling 364 shares during the period. Bruce G. Allen Investments LLC’s holdings in GSK were worth $223,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GSK. Dorsey & Whitney Trust CO LLC lifted its stake in GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after purchasing an additional 278 shares in the last quarter. Northwest Bank & Trust Co increased its holdings in shares of GSK by 1.3% in the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company’s stock worth $765,000 after purchasing an additional 289 shares during the last quarter. GC Wealth Management RIA LLC increased its holdings in shares of GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after purchasing an additional 353 shares during the last quarter. Rhumbline Advisers lifted its position in shares of GSK by 2.1% in the first quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company’s stock worth $713,000 after buying an additional 386 shares in the last quarter. Finally, Jacobi Capital Management LLC boosted its stake in GSK by 3.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock valued at $352,000 after buying an additional 389 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of GSK stock opened at $41.22 on Monday. The stock has a market cap of $84.48 billion, a price-to-earnings ratio of 25.92, a price-to-earnings-growth ratio of 1.12 and a beta of 0.52. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a 50 day moving average price of $37.59 and a 200-day moving average price of $36.43. GSK plc has a one year low of $31.72 and a one year high of $44.67.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. GSK’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the company earned $0.43 earnings per share. Equities analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. This represents a $1.69 annualized dividend and a dividend yield of 4.09%. The ex-dividend date of this dividend is Friday, May 16th. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is 86.60%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Berenberg Bank reaffirmed a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Hsbc Global Res raised shares of GSK to a “strong sell” rating in a report on Monday, April 28th. BNP Paribas initiated coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price target on the stock. Morgan Stanley assumed coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, Wall Street Zen lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, May 30th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, GSK has a consensus rating of “Hold” and an average target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.